Tudor Investment Corp
XENE icon

Tudor Investment Corp’s Xenon Pharmaceuticals XENE Stock Holding History

Tudor Investment Corp’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9M Buy
545,387
+49,796
+10% +$2.76M 0.05% 307
2026
Q1 		$28.8M Buy
495,591
+241,589
+95% +$11.1M 0.05% 288
2025
Q4 		$11.4M Buy
254,002
+177,178
+231% +$7.44M 0.02% 662
2025
Q3 		$3.08M Buy
+76,824
New +$2.71M 0.01% 1519
2025
Q1 		– Sell
-8,671
Closed -$340K – 3776
2024
Q4 		$340K Sell
8,671
-28,016
-76% -$1.16M ﹤0.01% 2511
2024
Q3 		$1.44M Buy
36,687
+11,455
+45% +$462K 0.01% 1406
2024
Q2 		$984K Buy
25,232
+75
+0.3% +$3K 0.01% 1467
2024
Q1 		$1.08M Sell
25,157
-18,064
-42% -$831K 0.01% 1299
2023
Q4 		$1.99M Buy
+43,221
New +$1.53M 0.02% 1097
2023
Q2 		– Sell
-29,908
Closed -$1.07M – 3002
2023
Q1 		$1.07M Buy
+29,908
New +$1.1M 0.02% 1153
2022
Q3 		– Sell
-20,336
Closed -$619K – 2767
2022
Q2 		$619K Buy
+20,336
New +$615K 0.02% 1150

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Tudor Investment Corp's XENE Position: Q2 2026 in Review

Tudor Investment Corp increased its Xenon Pharmaceuticals (XENE) stake by 10% in Q2 2026, buying an estimated $2.76M and bringing the position to 545,387 shares worth $32.9M. The position accounts for 0.05% of the portfolio, ranked #307.

Tudor Investment Corp first reported a position in XENE in Q2 2022 and has held it in 11 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Tudor Investment Corp held 545,387 shares of Xenon Pharmaceuticals worth $32.9M as of Q2 2026.
  • Tudor Investment Corp bought 49,796 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.76M.
  • Xenon Pharmaceuticals made up 0.05% of Tudor Investment Corp's portfolio in Q2 2026, its #307 holding.
  • Tudor Investment Corp first reported a position in Xenon Pharmaceuticals in Q2 2022 and has held it in 11 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.